A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia

Cancer Investigation

Volumn 28, Issue 3, 2010, Pages 312-322

  Liu, Jia ^a   Mittendorf, Thomas ^a   Von Der Schulenburg, J Matthias ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Health related quality of life; Hepatocellular carcinoma; Kidney cancer; Leukemia; Patient reported outcome; Quality of life

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ALPHA2A INTERFERON; AZACITIDINE; CYTARABINE; FLUDARABINE PHOSPHATE; FLUOROURACIL; IMATINIB; INTERFERON; INTERLEUKIN 2; IODINATED POPPYSEED OIL; IODINE 131; OCTREOTIDE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; SUNITINIB; TAMOXIFEN; YTTRIUM 90;

ARTICLE; BRIEF FATIGUE INVENTORY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LINEAR ANALOG SCALE; CENTRE FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CHEMOEMBOLIZATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT TOOL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA; FUNCTIONAL ASSESSMENT OF CANCER THERAPY BIOLOGIC RESPONSE MODIFIER; FUNCTIONAL ASSESSMENT OF CANCER THERAPY FATIGUE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; FUNCTIONAL ASSESSMENT OF CANCER THERAPY HEPATOBILIARY; FUNCTIONAL ASSESSMENT OF CANCER THERAPY KIDNEY SYMPTOM INDEX; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUND GERONTOLOGICAL CENTRE QUESTIONNAIRE; MCCORKLE AND YOUNG SYMPTOM DISTRESS SCALE; MEDICAL LITERATURE; MEDLINE; MENTAL HEALTH INVENTORY; PEDIATRIC QUALITY OF LIFE INVENTORY; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS; QUALITY OF LIFE QUESTIONNAIRE C 30; QUESTIONNAIRE; RADIOFREQUENCY ABLATION; RATING SCALE; SENSE OF COHERENCE SCALE; SHORT FORM 36; SPITZER QUALITY OF LIFE INDEX; SYMPTOM CHECKLIST 90; TREATMENT OUTCOME; WELLBEING;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CHILD; CHILD, PRESCHOOL; HUMANS; KIDNEY NEOPLASMS; LEUKEMIA; LIVER NEOPLASMS; MENTAL HEALTH; QUALITY OF LIFE;

EID: 77149137763     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903287022     Document Type: Article

References (72)

1. National Cancer Institute. Costs of Cancer Care, Cancer Trends Progress Report. Bethesda, MD: National Cancer Institute, 2007.
2. Food and Drug Administration (FDA). Guidance for Industry: Patient-Reported Outcome Measures Used in Medical Product Development to Support Labeling Claims, Draft Guidance. Available at: http://www.fda.gov/cber/gdlns/ prolbl.htm (accessed on Feb 11, 2009).
3. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: ACS, 2008.
4. Dimitroulopoulos, D.; Xinopoulos, D.; Tsamakidis, K.; et al. Long-acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007, 13 (23), 3164-3170.
5. El-Serag, H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127, S27-S34.
6. Tengs, T.O.; Wallace, A. One thousand health-related quality-of-life estimates. Med Care 2000, 38, 583-637.
7. Garratt, A.; Schmidt, L.; Mackintosh, A.; Fitzpatrick, R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002, 324, 1417.
8. Heinzer, H.; Mir, T.S.; Huland, E.; Huland, H. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 1999, 17, 3612-3620.
9. Motzer, R.J.; Murphy, B.A.; Bacik, J.; et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 18, 2972-2980.
10. Dutcher, J.P.; Logan, T.; Gordon, M.; et al. Phase II trial of inter-leukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000, 6, 3442-3450.
11. Tannir, N.M.; Cohen, L.; Wang, X.; et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006, 107, 2254-2261.
12. Negrier, S.; Perol, D.; Ravaud, A.; et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007, 110, 2468-2477.
13. Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24, 16-24.
14. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356, 115-124.
15. Cella, D.; Li, J.Z.; Cappelleri, J.C.; Bushmakin, A.; Charbonneau, C.; Kim, S.T.; Chen, I.; Motzer, R.J. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 2008 (Aug 1), 26 (22), 3763-3769.
16. Kouroumalis, E.; Skordilis, P.; Thermos, K.; Vasilaki, A.; Moschandrea, J.; Manousos, O.N. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998, 42, 442-447.
17. Yuen, M.F.; Poon, R.T.; Lai, C.L.; et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002, 36, 687-691.
18. Becker, G.; Allgaier, H.P.; Olschewski, M.; Zähringer, A.; Blum, H.E.; HECTOR study group. long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled doubleblind study. Hepatology 2007, 45, 9-15.
19. Verset, G.; Verslype, C.; Reynaert, H.; et al. Efficacy of the combination of long-acting release octreotide and tomoxiifen in patients with advanced hepatocellular carcinoma: a randomized multicentre phase III study. Br J Cancer 2007, 97, 582-588.
20. Chow, P.K.; Tai, B.C.; Tan, C.K.; et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002, 36, 1221-1226.
21. Barbare, J.C.; Bouché, O.; Bonnetain, F.; et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005, 23, 4338-4346.
22. Steel, J.; Baum, A.; Carr, B. Quality of life in patients diagnosed with primapry hepatocellular carcinoma: hepatic arterial infusion of cisplatin versus 90-yttrium microspheres (therasphere). Psy-chooncology 2004, 13, 73-79.
23. Yeo, W.; Mo, F.K.; Koh, J.; et al. Quality of life is predictive of survival in patients with unresctable hepatocellular carcinoma. Ann Oncol 2006, 17, 1083-1089.
24. Brans, B.; Lambert, B.; De Beule, E.; et al. Quality of life assessment in radionuclide therapy: a feasibility study of the EORTC QLQ-C30 questionnaire in palliative 131I-lipiodol therapy. Eur J Nucl Med Mol Imaging 2002, 29, 1374-1379.
25. Wang, Y.B.; Chen, M.H.; Yan, K.; Yang, W.; Dai, Y.; Yin, S.S. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res 2007, 16, 389-397.
26. Rossi, J.F.; van Hoof, A.; de Boeck, K.; et al. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2004, 22, 1260-1267.
27. Holzner, B.; Kemmler, G.; Kopp, M.; et al. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol 2004, 72, 381-389.
28. Shanafelt, T.D.; Bowen, D.; Venkat, C.; et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 2007, 139, 255-264.
29. Littlewood, T.J.; Bajetta, E.; Nortier, J.W.; et al. Effects of epo-etin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19, 2865-2874.
30. Ö sterborg, A.; Brandberg, Y.; Molostova, V.; et al. Randomized, double-blind, placebo-controlled trial of recombinant human ery-thropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002, 20, 2486-2494.
31. Hahn, E.A.; Glendenning, G.A.; Sorensen, M.V.; et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytara-bine: results from the IRIS study. J Clin Oncol 2003, 21, 2138-2146.
32. Kluin-Nelemans, H.C.; Buck, G.; le Cessie, S.; et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 2004, 103, 4408-4415.
33. Persson, L.; Larsson, G.; Ohlsson, O.; Hallberg, I.R. Acute leukemia or highly malignant lymphoma patients' quality of life over two years: a pilot study. Eur J Cancer Care 2001, 10, 36-47.
34. Kornblith, A.B.; Herndon, J.E.; Silverman, L.R.; et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol 2002, 20, 2441-2452.
35. Kantarjian, H.; Issa, J.P.; Rosenfeld, C.S.; et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106, 1794-1803.
36. Eiser, C.; Vance, Y.H.; Glaser, A.; et al. Growth hormone treatment and quality of life among survivors of childhood cancer. Horm Res 2005, 63, 300-304.
37. Sheppard, L.; Eiser, C.; Davies, H.A.; et al. The effects of growth hormone treatment on health-related quality of life in children. Horm Res 2006, 65, 243-249.
38. Reinfjell, T.; Lofstad, G.E.; Veenstra, M.; Vikan, A.; Diseth, T.H. Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukemia. Acta Paediatr 2007, 96, 1280-1285.
39. Link, K.; Moëll, C.; Osterberg, K.; Persson, R.; et al. Adult survivors of childhood acute lymphoblastic leukemia with GH deficiency have normal self-rated quality of life but impaired neuropsycholog-ical performance 20 years after cranial irradiation. Clin Endocrinol (Oxf) 2006, 65, 617-625.
40. Brooks, R. EuroQol: the current state of play. Health Policy 1996, 37, 53-72.
41. Mor, V.; Labiberte, L.; Morris, J.N.; Wiemann, M. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 1984, 53, 2002-2007.
42. Ware, J.E.; Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Medical Care 1992, 30, 473-483.
43. Ware, J.E.; Snow, K.K.; Kosinski, M.K.; et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: Nimrod Press, 1993.
44. Nordbeck, B.; Hagberg, B.; Jadbeck, G.; et al. Stroke patients in Sweden. Paper presented at the Fifteenth World Congress of Genrontology, Budapest, Hungary, 1992.
45. Antonovsky, A. The structure and properties of the sense of coherence scale. Soc Sci Med 1993, 36, 725-733.
46. Varni, J.W.; Seid, M.; Kurtin, P.S. Peds QL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001, 39, 800-812.
47. Aaronson, N.K.; Ahmedzai, S.; Bergman, B.; et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365-376.
48. Cella, D.F.; Tulsky, D.S.; Gray, G.; et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11, 570-579.
49. Spitzer, W.O.; Dobson, A.J.; Hall, J.; et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physician. J Chronic Dis 1981, 34, 585-597.
50. Heffernan, N.; Cella, D.; Webster, K.; et al. Health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol 2002, 20, 2229-2239.
51. Sutherland, H.J.; Walker, P.; Till, J.E. The development of a method for determining oncology patients' emotional distress using linear analogue scales. Cancer Nurs 1988, 11, 303-308.
52. Bacik, J.; Mazumdar, M.; Murphy, B.A.; et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 2004, 13, 137-154.
53. Yellen, S.B.; Cella, D.F.; Webster, K.; Blendowski, C.; Kaplan, E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997, 13, 63-74.
54. Cella, D.; Yount, S.; Du, H.; et al. Development and validation of the functional assessment of cancer therapy-kidney symptom index (FKSI). J Support Oncol 2006, 4, 191-199.
55. McCorkle, R. The measurement of symptom distress. Semin Oncol Nurs 1987, 3, 248-256.
56. McCorkle, R.; Young, K. Development of a symptom distress scale. Cancer Nurs 1978, 1, 373-378.
57. Radloff, L.S. The use of the center or epidemiologic studies depression scale in adolescents and young adults. J Youth Adolesc 1977, 20, 149-166.
58. Cella, D. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997, 34, 13-19.
59. Mendoza, T.R.; Wang, X.S.; Cleeland, C.S.; et al. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 1999, 85, 1186-1196.
60. Veit, C.T.; Ware, J.E. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol 1983, 51, 730-742.
61. Derogatis, L.R. SCL-90-R, Administration, Scoring and Procedures Manual I for the Revised Version of the SCL-90. Baltimore, MD: Johns Hopkins University Press, 1977.
62. McKenna, S.; Doward, L.C.; Alonso, J.; et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999, 8, 373-383.
63. Blazeby, J.M.; Currie, E.; Zee, B.C.; et al. Development of a questionnaire module to supplement the EORTC QLQ C-30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer 2004, 40, 2439-2444.
64. Steel, J.L.; Eton, D.T.; Cella, D.; Olek, M.C.; Carr, B.I. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol 2006, 17, 304-312.
65. Eton, D.T.; Cella, D.; Bacik, J.; Motzer, R.J. A brief symptom index for advanced renal cell carcinoma. Health Qual life Outcomes 2006, 26 (4), 68.
66. Cella, D.; Yount, S.; Brucker, P.S.; et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 2007, 10, 285-293.
67. Harding, G.; Cella, D.; Robinson, D., Jr; Mahadevia, P.J.; Clark, J.; Revicki, D.A. Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes 2007, 14 (5), 34.
68. Zittoun, R.; Achard, S.; Ruszniewski, M. Assessment of quality of life during intensive chemotherapy or bone marrow transplantation. Psychooncology 1999, 8, 64-73.
69. Zittoun, R.; Suciu, S.; Watson, M.; et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autolo-gous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant 1999, 20, 307-315.
70. Holzner, B.; Bode, R.K.; Hahn, E.A.; et al. Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. Eur J Cancer 2006, 42, 3169-3177.
71. Marquis, P.; Chassany, O.; Abetz, L. A comprehensive strategy for the interpretation of quality-of-life data based on existing methods. Value Health 2004, 7, 93-104.
72. Pickard, A.S.; Topfer, L.A.; Feeny, D.H. A structured review of studies on health-related quality of life and economic evaluation in pe-diatric acute lymphoblastic leukemia. J Natl Cancer Inst Monogr 2004, 33, 102-125.